# Breast Cancer Liver Metastasis: How It Spreads, Why It Happens, and What It Means for Patients Breast cancer liver metastasis (BCLM) is a complex process in which breast cancer cells spread to the liver, and it represents one of the most serious complications of breast cancer. This review article explains how breast cancer cells travel to the liver, why the liver environment is uniquely suited to hosting these cells, and what this means for treatment options. The data show that the 5-year survival rate for breast cancer drops from over 90% to less than 20% once cancer spreads to distant organs, and untreated liver metastasis offers only 4 to 8 months of survival. Understanding the interaction between cancer cells and the liver's cellular environment is essential for developing better treatments. # Breast Cancer Liver Metastasis: How It Spreads, Why It Happens, and What It Means for Patients ## Table of Contents - Key Points - Introduction: Why This Research Matters - Why Breast Cancer Spreads to the Liver: Organ Tropism - The Six Phases of Breast Cancer Liver Metastasis - The Liver Microenvironment: The "Soil" That Supports the "Seed" - Prognostic Factors: What Determines Outcomes - Clinical Implications: What This Means for Treatment - Limitations of Current Knowledge - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - Once breast cancer spreads to distant organs, the 5-year survival rate drops from over 90% to less than 20%. - Untreated breast cancer liver metastasis offers only 4 to 8 months of survival. - Breast cancer subtypes show organ tropism: HER-2 and basal-like tumors often spread to liver, lungs, and brain. - Crosstalk between breast cancer cells and liver tissue components determines whether liver metastasis develops. - No standard therapy specifically for breast cancer liver metastasis existed as of October 2022; current options include chemo, immunotherapy, targeted therapy, radiotherapy, and palliative care. ## Introduction: Why This Research Matters Breast cancer is the most common malignant disease in women worldwide. Thanks to improvements in screening and treatment, the 5-year survival rate for breast cancer is now over 90%. However, about 50% of patients diagnosed with breast cancer will eventually develop distant metastases (cancer that spreads to other organs). Once that happens, the 5-year survival rate declines dramatically to less than 20%. Breast cancer can spread to almost every place in the human body, but it most frequently travels to the lymph nodes, bones, lungs, liver, and brain. The liver is the third most common metastatic site for breast cancer. When breast cancer spreads to the liver — a condition called breast cancer liver metastasis, or BCLM — patients often suffer deterioration of liver function as the cancer burden increases, a situation that can threaten their lives. The numbers are sobering. If BCLM is left untreated, survival is only **4 to 8 months**. Yet, as of this review's publication in October 2022, no standard therapy has been established specifically for BCLM. Current treatment options include chemotherapy, immunotherapy (for triple-negative disease), targeted systemic therapies including endocrine therapy (for luminal subtypes), HER-2 targeted therapy (for HER-2 enriched subtypes), radiotherapy, and palliative (comfort-focused) therapy. Unfortunately, patients with BCLM frequently respond poorly to these therapies and experience high mortality rates. This review, published in the journal *Frontiers in Oncology*, aims to summarize recent advances in understanding the molecular mechanisms of the hepatic (liver) microenvironment in BCLM formation. The authors also discuss current systemic therapies and potential new treatments based on liver microenvironment-associated signaling proteins. This knowledge could be key to developing more effective therapy and prevention strategies for BCLM. ## Why Breast Cancer Spreads to the Liver: Organ Tropism Not all breast cancers behave the same way. Researchers have long observed that different breast cancer subtypes show distinct preferences for spreading to specific organs — a phenomenon called **organ tropism**. Breast cancer subtypes, identified through gene expression profiling, include: - **Luminal A** and **Luminal B** (hormone-receptor-positive types) - **Luminal/HER-2** (a mixed type) - **HER-2 enriched** (human epidermal growth factor receptor 2 positive) - **Basal-like** (often referred to as triple-negative breast cancer) - **Triple-negative (TN) non-basal** Luminal breast cancer preferentially metastasizes to the bones, while HER-2 and basal-like breast cancers often develop visceral (internal organ) metastases, including to the brain, liver, and lungs. Some studies report that the HER-2 enriched subtype has a higher risk of developing liver metastasis. Other studies report that basal-like breast cancer has a lower rate of liver metastasis. Although there are some discrepancies in reports about preferred organ sites, it is now accepted that particular metastatic sites are associated with different breast cancer subtypes. Why does breast cancer favor certain organs? It was once thought that "mechanical arrest" — cancer cells simply being physically trapped in the small blood vessels (capillaries) of an organ — explained where cancer spread. But organs that receive similar amounts of blood and similar numbers of circulating tumor cells show differing abilities to accommodate breast cancer cells and form metastases. This finding indicates that mechanical arrest is not the only explanation for organ tropism. Instead, the **"seed and soil"** hypothesis proposes that metastases form only when the disseminated breast cancer cells (the "seed") are compatible with the distant organ's microenvironment (the "soil"). The ability of breast cancer cells to interact with tissue-resident cells and microenvironmental factors may determine the metastatic organs of breast cancer. In other words, the crosstalk between breast cancer cells and liver tissue components provides key mechanisms that dictate whether BCLM develops. ## The Six Phases of Breast Cancer Liver Metastasis The formation of BCLM involves a series of complex biological processes. First, breast cancer cells undergo **epithelial-to-mesenchymal transition (EMT)** — a process in which cells lose their "epithelial" (tightly connected) characteristics and gain "mesenchymal" (mobile, invasive) characteristics. They then detach from the primary tumor and enter the bloodstream (intravasate) through endothelial barriers. Macrophages and mesenchymal stem cells (MSCs) contribute to EMT at the primary breast cancer site. Cancer-associated fibroblasts (CAFs) and myeloid progenitor cells are recruited to the invasive edge of the primary tumor and promote intravasation. Platelets also help breast cancer cells survive in circulation as they travel to extravasation sites. After circulating tumor cells squeeze out of blood vessels (extravasate) into the liver tissue, they will either enter a dormant (sleeping) state or form clinically detectable macrometastases. Researchers have broken down this entire journey into **six distinct phases**: 1. **The intravasation phase:** Primary breast cancer cells detach from surrounding cells and enter the circulation system. Cells involved include mesenchymal stem cells, macrophages, endothelial cells, platelets, cancer-associated fibroblasts, myeloid progenitor cells, dendritic cells, and neutrophils. 1. **The premetastatic phase:** A "premetastatic niche" forms in the liver — a welcoming environment that permits breast cancer cells to enter and grow. Hepatic stellate cells, cancer-associated fibroblasts, Kupffer cells, myeloid-derived suppressor cells, regulatory T cells, and neutrophils all play roles in establishing this niche. 1. **The tumor-infiltrating microvascular phase:** Breast cancer cells arrest in the sinusoidal vessels (the liver's specialized small blood vessels) and then extravasate into the liver tissue, with help from M2 macrophages, hepatic stellate cells, cancer-associated fibroblasts, neutrophils, liver sinusoidal endothelial cells, hepatocytes, and Kupffer cells. 1. **The pre-angiogenic micrometastatic phase:** The host's stromal (support) cells are recruited into avascular micrometastases (small clusters of cancer cells that do not yet have a blood supply). M2 macrophages, liver sinusoidal endothelial cells, neutrophils, hepatic stellate cells, and Kupffer cells are involved. 1. ## Frequently Asked Questions ### Why does breast cancer spread to the liver? Breast cancer cells travel through the bloodstream, but they only form liver tumors if they are compatible with the liver's environment. This is called the 'seed and soil' idea. Certain breast cancer types, such as HER-2 enriched, may have a higher risk of spreading to the liver. ### What are the six phases of breast cancer liver metastasis? The process includes: entering the bloodstream, forming a welcoming premetastatic niche in the liver, stopping in liver blood vessels and moving into liver tissue, growing into small clusters without blood supply, developing a blood supply, and then forming detectable tumors. Many liver cells and immune cells help this happen. ### How long can someone live with untreated breast cancer liver metastasis? According to the article, if breast cancer liver metastasis is left untreated, survival is only 4 to 8 months. This shows how serious liver metastasis is. That is why doctors focus on early detection and treatment, even though no standard therapy has been established specifically for this condition. ### What treatments are available for breast cancer liver metastasis? Current options include chemotherapy, immunotherapy for triple-negative disease, endocrine therapy for hormone-receptor-positive types, HER-2 targeted therapy for HER-2 enriched tumors, radiotherapy, and palliative care. Unfortunately, patients with liver metastasis often respond poorly to these treatments and may have high death rates. ### Which breast cancer subtypes are more likely to spread to the liver? HER-2 enriched and basal-like breast cancers often develop internal organ metastases, including to the liver, lungs, and brain. Luminal types more often spread to bone. One study reported HER-2 enriched subtype has a higher risk of liver metastasis, while another reported basal-like has a lower rate. ### Why doesn't breast cancer spread to every organ equally? Mechanical trapping in small blood vessels is not the only reason. Organs that receive similar blood flow can still differ in how easily breast cancer grows there. The 'seed and soil' hypothesis explains that the cancer cell must be compatible with the organ's environment, so the liver's cells and signals determine whether metastasis forms. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/breast-cancer-liver-metastasis-how-it-spreads-why-it-happens-and-what-it-means-for-patients